AGC Biologics shifts leadership structure at US and Copenhagen sites
With more than 1,400 employees, company focuses on development through to commercialization
AGC Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO), has announced leadership changes at
its US and Copenhagen, Denmark
operations. The changes became effective
October 15
.
Jeffrey D. Mowery, formerly general manager of the Copenhagen site,
joins the global executive team at the company's headquarters in Seattle as senior vice president of US operations.
Mowery, with more than 20 years of experience in small molecule, biologic and cell and gene therapy production and technology transfer, will oversee AGC’s new
Boulder, CO
facility rollout and progress at its expanding
Seattle
site.
Andrea C. Porchia was
promoted to succeed Mowery in the Denmark facility as general manager and site head for Copenhagen. She previously served in a variety of roles ranging from project director and business development representative to global head of project management.
She has more than two decades of research and process experience and will have a critical focus on project management and customer service, according to AGC.
AGC Biologics, with more than 1,400 employees worldwide, focuses on all phases of development through to commercialization, with expertise in process development, formulation, and analytical testing. Its global service network maintains US locations in
Seattle
and
Boulder, as well as operations
in
Denmark,
Italy, Germany and Japan.
